Abliva AB has gone above its market capitalization to raise the money it needs to start a phase II/III trial of KL-1333 for the treatment of primary mitochondrial disease.

Healthquest Capital Management Co. LLC closed its oversubscribed fourth fund at its hard cap of $675 million, positioning the equity firm to ramp up its investment at the “convergent points between medical technologies, diagnostics/tools, digital health and innovative services,” the company said.